The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
The SARS-CoV-2 virus, the pathogen causing COVID-19, has caused more than 200 million
confirmed cases, resulting in more than 4.5 million deaths worldwide by the end of August …
confirmed cases, resulting in more than 4.5 million deaths worldwide by the end of August …
[HTML][HTML] Recent advances in developing small-molecule inhibitors against SARS-CoV-2
R Xiang, Z Yu, Y Wang, L Wang, S Huo, Y Li… - … Pharmaceutica Sinica B, 2022 - Elsevier
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across
the entire world. Even though several COVID-19 vaccines are currently in distribution …
the entire world. Even though several COVID-19 vaccines are currently in distribution …
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
TA Tummino, VV Rezelj, B Fischer, A Fischer… - Science, 2021 - science.org
Repurposing drugs as treatments for COVID-19, the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …
Replication and single-cycle delivery of SARS-CoV-2 replicons
Molecular virology tools are critical for basic studies of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental …
syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental …
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential
B Meyer, J Chiaravalli, S Gellenoncourt… - Nature …, 2021 - nature.com
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, responsible for over
170 million infections, and over 3.7 million deaths worldwide. Efforts to test, treat and …
170 million infections, and over 3.7 million deaths worldwide. Efforts to test, treat and …
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal
Unprecedented efforts of the researchers have been witnessed in the recent past towards
the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit …
the development of vaccine platforms for the control of the COVID-19 pandemic. Albeit …
Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro
Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …
Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors
JK Stille, J Tjutrins, G Wang, FA Venegas… - European journal of …, 2022 - Elsevier
Severe diseases such as the ongoing COVID-19 pandemic, as well as the previous SARS
and MERS outbreaks, are the result of coronavirus infections and have demonstrated the …
and MERS outbreaks, are the result of coronavirus infections and have demonstrated the …
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Since the beginning of the COVID-19 pandemic, large in silico screening studies and
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
The 3C-like protease (3CLpro) of SARS-CoV-2 is considered an excellent target for COVID-
19 antiviral drug development because it is essential for viral replication and has a cleavage …
19 antiviral drug development because it is essential for viral replication and has a cleavage …